Athira Pharma, Inc.
Athira Pharma, Inc. (ATHA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ATHA · as of Jun 9, 2026
Key Statistics
Explore Athira Pharma, Inc. Data
atha stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 0.0%
The ATHA analyst consensus is Hold, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $13.33, representing +97.48% upside from the current price of $6.75.
Competitors & Peers
atha competitorsATHA
ADTX
APLM
CRIS
CTXR
DAREStock Performance
Full HistoryAbout Athira Pharma, Inc.
Athira Pharma, Inc. a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function …
what is athira pharma, inc. · atha stock overview · athira pharma, inc. company profile · who is athira pharma, inc. ceo · atha NASDAQ · athira pharma, inc. headquarters · athira pharma, inc. business segments
About Stock Overview & Key Data
Athira Pharma, Inc. (ATHA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 18, 2020. As of the latest trading session, ATHA stock price is $6.75, with a market capitalization of $26.6M. The stock has returned +53.06% over the past 12 months and -3.02% year-to-date.
According to 5 Wall Street analysts, the consensus rating for Athira Pharma, Inc. stock is Hold, with an average 12-month price target of $13.33. In fiscal year 2025, Athira Pharma, Inc. reported revenue of — and net income of -$105.6M. For detailed data — including Athira Pharma, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Athira Pharma, Inc. (ATHA) stock price is $6.75. The stock is traded on NASDAQ under the ticker symbol ATHA. The 52-week range is $2.20 – $8.36.